Acino broadens own brand portfolio through a licensing agreement with Neogen

Top Quote Acino continues its expansion towards global emerging markets under its own «Acino» brand by successfully in-licensing a portfolio of parenteral products from Belgium-based Neogen. End Quote
  • (1888PressRelease) July 07, 2011 - Through this in-licensing agreement Acino will strengthen its product offering in the therapeutic areas oncology and pain management where the company with its current portfolio of in-house developed products,
    has already built a strong franchise.

    Ruud van Anraat, Acino’s Chief Commercial Officer, said: “We expect to add more products which we consider good fits to our existing portfolio especially in the field of oncology and pain management as well as for the treatment of concomitant diseases. We see a strong growth of these molecules in our new target markets, and with the Neogen collaboration we will be able to enhance our current regional presences in the
    Middle East, Asia and Africa.”

    Neogen’s Managing Director Eric Dubois commented: “We are very happy to enter into this strategic collaboration with Acino which will open new markets to Neogen and expand our business in existing non-European markets. We believe that Acino - with its Swiss base, local market presence, and high quality standards - will be a strong partner, and we are proud to be involved in Acino’s expansion at an early stage.”

    As part of its expansion into emerging markets, Acino has so far already signed 22 contracts with local marketing partners covering 32 countries. “By using the regulatory and marketing expertise of these local partner companies, Acino will be better placed to capitalize on its existing product portfolio as well as its strong pipeline of new product launches”, Ruud van Anraat continued.

    Going forward, the Company expects to enter into more marketing contracts with partners for countries which have been identified as suitable for the Acino business model and its product offering. Under its own «Acino» brand, the company will be launching its in-house developed as well as in-licensed products which support the strategy of bringing Swiss/EU quality products to the emerging markets, making state of the art treatment regimes available to more patients at affordable prices.

    About Neogen
    Neogen, a privately owned Belgian company, develops difficult to manufacture parenteral formulations of well known molecules. Its products are produced in GMP-approved manufacturing sites, mainly located in Germany, Italy, and France. Neogen has licensees in 75 countries, a number that will increase further under the Acino collaboration.

    Acino - a focused pharmaceutical company
    Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops and manufactures generic and innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. With a focus on sophisticated oral dosage forms with modified release of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants, Acino supplies leading pharmaceutical companies worldwide. Acino offers the pharmaceutical industry a comprehensive range of services from product development and registration to sourcing, contract manufacturing, packaging and logistics. The Acino Group is headquartered in Basle (Switzerland), currently employs 443 staff and generated annual revenues of EUR 128 million in 2010.

  • FB Icon Twitter Icon In-Icon
Contact Information